GLP-1 Receptor Agonists – Extending access to more T2DM patients with chronic obesity (Webinar held on 10 April 2025)

shutterstock_2369994581 - home page

Improving the care of T2DM patients in South Africa; one of the ways of accomplishing this is to expand patient access to newer antidiabetic agents

Learning objectives

You will learn:

  • Understand the long-term benefits for your T2DM patients of the GLP-1RAs in terms of achieving better glycaemic control and reducing long-term CV, Renal and Metabolic complications over the duration of their diabetes
  • Encourage patients to adopt life-style changes and improve adherence and commitment to their therapeutic regimens which now offer much greater health benefits over the duration of their diabetes
  • Contribute to better health care by encouraging funders and public sector formularies to make these agents more accessible to South African patients as generic GLP-1RAs become available in the country.

To access this module, please register or login: